Immune checkpoint blockade therapies targeting programmed cell death protein 1 (PD-1) achieve marked clinical benefits in cancer patients harboring programmed death ligand-1 (PD-L1) expression tumours [1–6]. This evidence concerns the gene CD274 and cancer.